Phase 1 KRAS Mutation-Related Tumors Clinical Trials

3 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–3 of 3 trials

Recruiting

Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more

Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924

Recruiting

Phase 1

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Solid TumorKRAS Mutation-Related Tumors

Georgetown University24 enrolled1 locationNCT05661201

Recruiting

Phase 1Phase 2

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

Triple-Negative Breast CancerOvarian CancerCervical Cancer+3 more

University of California, Irvine67 enrolled1 locationNCT07064018